Key facts
- This page summarizes Laurie Keating's Form 4 filing for Imago BioSciences, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 11 Jan 2023, 15:23.
Laurie Keating - 11 Jan 2023 Form 4 Insider Report for Imago BioSciences, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 11 Jan 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Jan 2023, 15:23:43 UTC
- Prior SEC filing
- 23 Jun 2022
- Next SEC filing
- 15 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/Hugh Y. Rienhoff, as Attorney-in-fact for Laurie Keating
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Laurie Keating filed Form 4 for Imago BioSciences, Inc. on 11 Jan 2023.
Change
- Previous filing in this sequence was filed on 23 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMGO
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -23,809
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 23,809
- Exercise price
- $22.76
- Footnotes
- F1
IMGO
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -11,904
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,904
- Exercise price
- $15.65
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Laurie Keating is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option.